Farmers & Merchants Investments Inc. Has $203,000 Stock Position in Solventum Co. (NYSE:SOLV)

Farmers & Merchants Investments Inc. trimmed its position in shares of Solventum Co. (NYSE:SOLV) by 14.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,079 shares of the company’s stock after selling 500 shares during the quarter. Farmers & Merchants Investments Inc.’s holdings in Solventum were worth $203,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of SOLV. Hotchkis & Wiley Capital Management LLC bought a new position in shares of Solventum in the third quarter valued at about $125,488,000. Trian Fund Management L.P. raised its position in Solventum by 32.9% in the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after purchasing an additional 1,765,676 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Solventum in the 3rd quarter valued at $50,948,000. Nordea Investment Management AB increased its stake in shares of Solventum by 189.5% in the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock valued at $43,902,000 after buying an additional 431,986 shares during the period. Finally, Assenagon Asset Management S.A. raised its position in shares of Solventum by 4,765.0% during the third quarter. Assenagon Asset Management S.A. now owns 319,628 shares of the company’s stock worth $22,284,000 after acquiring an additional 313,058 shares during the last quarter.

Analyst Ratings Changes

SOLV has been the topic of a number of research reports. Mizuho assumed coverage on shares of Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price on the stock. Morgan Stanley raised their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Finally, Piper Sandler upped their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $68.29.

Solventum Trading Down 1.8 %

Shares of SOLV opened at $73.43 on Friday. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The firm’s 50 day moving average price is $70.40 and its two-hundred day moving average price is $67.94.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.15 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.23). The company had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.05 billion. As a group, research analysts forecast that Solventum Co. will post 6.58 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.